Description
Clinical Description
Rejuran I PN (1 × 1ml) is a professional polynucleotide (PN) injectable skin booster specifically formulated for delicate skin areas, particularly aesthetic applications around the periocular region. It belongs to the category of regenerative skin treatments that use purified polynucleotide technology to support skin quality improvement.
Unlike traditional dermal fillers based on hyaluronic acid gel technology, Rejuran I is not primarily designed for volume replacement. Instead, it uses polynucleotide molecules derived from purified DNA fragments to support the dermal environment and promote improvements in skin texture and elasticity.
Manufactured by PharmaResearch Co., Ltd., Rejuran I forms part of the Rejuran range of PN-based aesthetic products. The formulation is designed for professional use where practitioners seek targeted skin rejuvenation solutions, particularly for areas requiring delicate treatment approaches.
The exact polynucleotide concentration, excipients, and full formulation specifications should be confirmed through the official manufacturer documentation and product IFU.
What Rejuran I PN Is Similar To
Rejuran I belongs to the polynucleotide skin booster category and can be compared with other regenerative injectable treatments, including other products within the Rejuran range.
Compared with Rejuran Healer PN (2 × 2ml), Rejuran I uses the same general polynucleotide technology but is positioned for more targeted applications involving delicate skin areas. Rejuran Healer is commonly associated with broader skin rejuvenation procedures, while Rejuran I is often selected for areas where a more specialised formulation is required.
Rejuran I can also be compared with hyaluronic acid-based eye-area skin boosters. While both categories may be used for improving skin quality, their mechanisms differ. Hyaluronic acid products rely on HA hydration and tissue interaction properties, whereas Rejuran I uses polynucleotide technology designed to support the skin’s regenerative environment.
Treatment choice depends on product indications, practitioner assessment, and manufacturer guidance.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
Based on available product information, Rejuran I PN is intended for professional aesthetic applications involving delicate skin rejuvenation.
Reported treatment application:
- Periocular area / under-eye region
- Delicate facial skin areas requiring skin quality improvement
Rejuran I is commonly positioned within the Rejuran range as a formulation designed specifically for thinner and more sensitive skin areas.
Specific approved anatomical indications and treatment areas should be confirmed through the official manufacturer Instructions for Use (IFU).
Usage / Administration (IFU-Only Section)
Rejuran I PN (1 × 1ml) should only be administered by qualified medical professionals trained in injectable aesthetic procedures.
Administration must follow the official manufacturer Instructions for Use.
Treatment should be performed under appropriate aseptic conditions and according to professional medical-device standards.
Some practitioners describe specific micro-injection techniques for polynucleotide products; however, these methods are not considered official Rejuran I manufacturer guidance unless included within the product IFU.
Ingredient List
Rejuran I contains polynucleotide (PN) as its key active component.
Available formulation information:
- Polynucleotide (PN) – purified DNA-derived biopolymer used as the main active ingredient in the formulation.
The complete ingredient profile should be verified through the official manufacturer product documentation supplied with the device.
Presentation & Longevity
Presentation
Rejuran I PN is supplied as:
- 1 × 1ml syringe
The product is intended for professional aesthetic use and should be stored and handled according to manufacturer requirements.
Longevity
As a polynucleotide-based injectable, Rejuran I is designed to support gradual improvement in skin quality rather than immediate volume correction associated with traditional dermal fillers.
The duration of visible effects can vary depending on:
- individual skin characteristics,
- treatment area,
- practitioner protocol,
- biological response.
A specific manufacturer-confirmed longevity period for Rejuran I PN was not identified in publicly available documentation.
Safety Notes / Contraindications
Rejuran I PN (1 × 1ml) is an injectable polynucleotide medical aesthetic device intended for use by qualified healthcare professionals with appropriate training and experience in aesthetic injection procedures.
Before treatment, practitioners should perform a suitable patient assessment and review medical history, allergies, previous procedures, and any potential contraindications according to the manufacturer’s Instructions for Use.
Important safety considerations include:
- Use is contraindicated in patients with known hypersensitivity to any component of the product.
- Treatment should not be performed in areas with active skin infections, inflammation, or compromised skin conditions.
- Patients with known sensitivity to product ingredients or a history of significant injection-related reactions should be assessed carefully before treatment.
- The product should only be used according to the approved indications and manufacturer instructions.
As with other injectable aesthetic procedures, temporary local reactions may occur, including redness, swelling, bruising, tenderness, itching, or discomfort at the injection site.
Patients should understand that outcomes vary depending on individual skin characteristics, treatment area, practitioner technique, and biological response.
Regulatory Status
Rejuran I PN is marketed as a professional polynucleotide-based injectable aesthetic device manufactured by PharmaResearch Co., Ltd.
Available product information identifies:
- Product category: Polynucleotide (PN) skin booster
- Presentation: 1 × 1ml syringe
- Intended users: Qualified medical aesthetic professionals
- Manufacturer: PharmaResearch Co., Ltd.
Regulatory classification and market availability may differ depending on country and intended use. Practitioners should confirm current product labelling, certification documentation, and applicable regulatory requirements before administration.
Regulatory classification not fully specified in publicly available documentation; verify on the product packaging or manufacturer’s IFU.
FAQ
1. What is Rejuran I PN (1 × 1ml) and how does it work?
Rejuran I PN is a polynucleotide-based injectable designed for professional aesthetic applications involving delicate skin areas. Its active component is purified polynucleotide (PN), a DNA-derived biopolymer technology used within regenerative aesthetic treatments.
Unlike conventional dermal fillers that primarily provide volume through gel implantation, Rejuran I is categorised as a skin booster designed to support skin quality-related processes. The product is commonly associated with improving the appearance and condition of delicate skin areas, particularly where practitioners seek a specialised PN formulation.
2. What makes Rejuran I different from Rejuran Healer?
Rejuran I and Rejuran Healer both use polynucleotide technology and belong to the same product family. The main difference is their intended application focus.
Rejuran I is generally positioned for delicate areas such as the periocular region, where a specialised approach may be required. Rejuran Healer is commonly used as a broader skin rejuvenation formulation.
Although both products share PN technology, they are separate products with different positioning and should be selected according to manufacturer information, practitioner assessment, and treatment objectives.
3. How does Rejuran I compare with hyaluronic acid eye-area treatments?
Rejuran I and hyaluronic acid-based eye-area treatments represent different injectable categories.
Rejuran I uses polynucleotide technology derived from purified DNA fragments, while HA-based products rely on hyaluronic acid properties such as hydration and tissue interaction.
Both approaches may be used in aesthetic medicine for improving the appearance of delicate skin areas, but they differ in composition, mechanism, and product indications.
Practitioners should select products based on patient assessment and the manufacturer’s approved information.
4. How long do results from Rejuran I last?
The duration of visible effects following Rejuran I treatment varies depending on individual factors, including skin condition, treatment area, practitioner protocol, and biological response.
Polynucleotide-based treatments are designed around gradual skin-quality improvement rather than immediate volumising effects. The timeline and duration of results should be evaluated according to manufacturer information and professional clinical assessment.
A specific manufacturer-confirmed longevity period for Rejuran I PN was not identified in publicly available documentation.
Treatment duration: not provided by manufacturer.
5. Who can administer Rejuran I PN (1 × 1ml)?
Rejuran I PN should only be administered by qualified healthcare professionals who have appropriate training and experience in injectable aesthetic procedures.
The practitioner is responsible for:
- assessing patient suitability,
- reviewing contraindications,
- following the manufacturer’s IFU,
- maintaining appropriate aseptic conditions.
Patients considering treatment should consult a qualified medical professional who can determine whether the product is suitable based on individual circumstances.
